Goldman Sachs Group Analysts Give MorphoSys (ETR:MOR) a €114.00 Price Target

Goldman Sachs Group set a €114.00 ($132.56) price objective on MorphoSys (ETR:MOR) in a research note issued to investors on Tuesday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

Other research analysts have also issued reports about the company. JPMorgan Chase & Co. set a €120.00 ($139.53) target price on MorphoSys and gave the company a buy rating in a research note on Wednesday, May 8th. Deutsche Bank set a €125.00 ($145.35) target price on MorphoSys and gave the company a buy rating in a research note on Friday, April 26th. Finally, Berenberg Bank set a €108.00 ($125.58) target price on MorphoSys and gave the company a buy rating in a research note on Tuesday, April 2nd. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average price target of €100.78 ($117.18).

Shares of ETR MOR opened at €85.50 ($99.42) on Tuesday. The company has a debt-to-equity ratio of 8.65, a current ratio of 7.75 and a quick ratio of 7.53. The firm has a market capitalization of $2.70 billion and a P/E ratio of -46.02. MorphoSys has a one year low of €76.45 ($88.90) and a one year high of €124.90 ($145.23).

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Read More: What does an equal weight rating mean?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit